Part of Avalere Health

The future isn’t something we wait for. It’s something we can build. Because the miraculous happens when we decide reaching EVERY PATIENT is POSSIBLE. Discover how our advisory, marketing, and medical experts partner with clients to build a world where no patient is left behind.

Explore Avalere Health

Services

Market Access

Implementation Science and Evaluation

Vaccines

Due Diligence

Patient-Centered Outcomes

Federal and State Policy

HEOR

Overview Helping life sciences companies successfully initiate and sustain product commercialization at each point along the access-and-commercialization continuum.

Overview Harnessing the power of implementation science to close the gap between evidence and practice and integrate evidence-based interventions into healthcare settings.

Overview Supporting clients in generating evidence and translating it into strong recommendations, influencing the policy environment, and shaping patient-access channels.

Overview Conducting continuous, thorough analysis of acquisition targets, uncovering potential risk factors, and identifying value critical to any transaction.

Overview Helping clients access and analyze information to understand patient perspectives and facilitating stakeholder conversations to gain insights on the patient experience.

Overview Providing clients with multistakeholder perspectives to help them anticipate, interpret, and respond to changes in the complex legislative and regulatory environment.

Overview Using our comprehensive real-world data access to develop real-world evidence that supports data-driven decision making and market differentiation.

Our Work in Action

Case Studies

Learn More

Our Clients

Who We Help

Our team has experience working at life sciences companies, health plans, private equity firms, and more.

Sarah Alwardt

President, Avalere

“Avalere’s work has tangible business impacts for our clients because we’ve been in their shoes. We back up our content knowledge with real-world experience.”

Avalere Avalere

We Are
Avalere Health.

CMS Announces Next 15 Drugs Selected for IRA Negotiation

Updated Resource: State Statute Oncology Drug Coverage Report

RxHCC Model May Not Accurately Predict Costs for Certain TAs

IRA Negotiation Impact on Part B Beneficiary OOP Costs

What the Election Results Mean for Health Policy in the Year Ahead

2025 Part D Formularies Shift to More Coinsurance and UM

2026 Part D Plan and Manufacturer Contracting Strategies

eBook: Navigating the Immunization Ecosystem

Accelerating Access through Payer Marketing